Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 43Thoracic 26Head & Neck 17Dermatologic 7Breast 7Other solid neoplasm 6Genitourinary 6Tumor-Agnostic 4Lymphoid 4Gynecologic 3CNS 3Sarcoma 2Other hematologic neoplasm 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

venetoclax 308Cyclophosphamide 231Cytarabine 201Azacitidine 191fludarabine 181Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 82Rituximab 79Daunorubicin 77Dexamethasone 76Vincristine 69Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 58Tacrolimus 55Etoposide 53ibrutinib 52blinatumomab 51Granulocyte Colony-Stimulating Factor 51obinutuzumab 50Busulfan 50Prednisone 49Melphalan 48acalabrutinib 47Injections 46Stem Cell Transplantation 45Idarubicin 45Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immune Checkpoint Inhibitors × Other hematologic neoplasm × 1 year × Clear all
NCT07541755 2026-04-21

PD1-VEN-CAG

Fujian Medical University Union Hospital

Phase 3 Active not recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡